Clinical Trials Browser

Phase 2 × Not yet recruiting × 30 days × Clear all

NCT05554419 2026-03-19

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06557733 2026-03-19

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase 2 Not yet recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT06708455 2026-03-19

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Phase 2 Not yet recruiting

Melanoma

NCT07149207 2026-03-19

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Phase 2 Not yet recruiting

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms

NCT07169617 2026-03-19

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Phase 2 Not yet recruiting

Lung Neoplasms

NCT07172256 2026-03-19

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07437950 2026-03-19

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07483359 2026-03-19

CONV3RSION

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06258525 2026-03-18

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Phase 2 Not yet recruiting

Classical hematologyGastrointestinal

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT06732388 2026-03-18

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06954987 2026-03-18

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07328503 2026-03-18

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07472933 2026-03-18

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

Phase 2 Not yet recruiting

Gastrointestinal

Cancer of Biliary Duct

NCT07479628 2026-03-18

Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma

Phase 2 Not yet recruiting

Thymoma

NCT07480733 2026-03-18

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07349641 2026-03-17

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Phase 2 Not yet recruiting

Endometrial Hyperplasia

NCT07470840 2026-03-17

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07475806 2026-03-17

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07476287 2026-03-17

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07476677 2026-03-17

ANDARP

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, B-Cell

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Phase 2 Not yet recruiting

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT07478523 2026-03-17

FAPDIG

Phase 2 Not yet recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05479045 2026-03-16

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07001995 2026-03-16

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07287098 2026-03-16

preEMBER

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07472478 2026-03-16

GIVEN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07474558 2026-03-16

SCARLET-ICE

Phase 2 Not yet recruiting

Alopecia

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07322341 2026-03-13

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07468916 2026-03-13

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Phase 2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Locally Advanced Rectal Cancer

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07470606 2026-03-13

MemoryRT

Phase 2 Not yet recruiting

Brain Neoplasms

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07450976 2026-03-12

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Urogenital Diseases, Prostatic Diseases

NCT07465757 2026-03-12

ALISCA-Lung2

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07466303 2026-03-12

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07466927 2026-03-12

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

Phase 2 Not yet recruiting

HER2-negative Breast Cancer

NCT07467590 2026-03-12

TRIUNITE-07

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms